How ESE is Funded
The following funding model has been deemed suitable for participating in EMA activities, acting in the interests of European patients, consumers and healthcare professionals. This evaluation was completed with reference to ESE funding for the 2021 financial year.
ESE is funded through a number of industry and non-industry sources:
- Membership – individual
- Membership – Corporate – See all our Corporate members
- Revenue generated by ESE owned journal ‘European Journal of Endocrinology’
- Revenue from industry into ECE and other educational programmes, principally through support of satellite sessions and exhibition stands and unrestricted educational grants in support of postgraduate education
- The list of all industry and non-industry revenue sources in 2021 are listed below:
- Ace Pharmaceuticals BV
- Addisons Disease Self Help Group (joint with CAH)
- Advanced Accelerator Applications France
- Alexion
- AMEND
- Amryt Pharmaceuticals DAC
- Ascendis Pharma
- Chiasma
- Clinical Endocrinology Trust
- Covidien AG
- Crinetics Pharmaceuticals Inc
- Diurnal Limited
- HRA Pharma rare diseases
- Inozyme Pharma
- International Medical Press
- Ipsen
- ITM Solution Gmbh
- King, Campbell & Friends (on behalf of Advanz Pharma)
- Kyowa kirin
- Novo Nordisk Health Care AG
- Parathyroid UK
- Pfizer Ltd
- Recordati AG
- Roche Diagnostics International Ltd
- Soleno Therapeutics
- Takeda Pharmaceuticals International AG
- Thyroid Federation International
- Uni Pharma Kleon Tsetis
- World Alliance of Pituitary Organizations (WAPO)
- Of the revenue into ESE in the 2021 accounts 47.3% was provided by industry.
- The highest contribution from a single company represented 15% of the industry revenue and 7.1% of ESE revenue overall.